5 Monster Stock Market Predictions – The Week of September 12, 2022, Edition

This column is my opinion and expresses my views. Those views can change at a moments notice when the market changes. I am not right all the time and I do not expect to be. I disclose all my positions clearly listed on the page, and I do not trade my account on the stocks spoken of in this column unless fully disclosed. If that does not work for you stop reading and close the page. Do not bother me or harass me.

Otherwise, enjoy the column!

Subscribe to the Monster Stock Market Commentary to get the Weekly Monster Market Commentary and join the 3,339 subscribers getting it for FREE!

The Daily Commentary has moved as of December 1, 2022

9/11/22

STOCKS –

MACRO – SPY, QQQ, TIP, XBI, 2-YR

Mike’s Reading The Markets (RTM) Premium Content – $65/MONTH OR $520/YEAR – The First 2-weeks are FREE to try – GET 20% OFF!

(The *Free Trial offer is not available in the app stores, it can only be applied on the desktop version of the SA website)

This week’s Free YouTube Video:

 

This week will be interesting, with inflation data Tuesday and Wednesday and quadruple witching on Friday. There will be a lot of big Treasury auctions this week, which will move yields and stocks. The one wrinkle is that the VIX options expiration doesn’t take place until Wednesday, September 21.

Options expiration will play a big part in what happens this week, and it could be more of an impact than the actual inflation data. At this point, the gamma levels suggest the S&P 500 is too far out in front of itself and needs to pull back down. Of course, these gamma levels change daily and could roll higher. But at this point, the region with the most significant amount of gamma on the S&P 500 is around 4,000, with 3,900 and 4,100 acting as the outside boundary for the puts and calls.

 

This tells us that depending on how these levels shift throughout the week, unless we see a significant amount of gamma start building up at higher levels, the S&P 500 could pull back towards 4,000. We also saw something similar happen in July and August, with the QQQ ETF running higher the week before options expiration and then falling back to its more significant gamma levels the week of options expiration.

A pullback would work from a technical perspective, as there are many strong Fibonacci relationships in the S&P 500 futures. The current move higher has retraced 50% of the drop from the mid-August highs to the September lows. Also, the rally has been a 1.618% extension starting on September 7.

An ending diagonal triangle also appears to form on Friday afternoon and probably suggests we see the S&P 500 futures pull back to around 4,000.

If this is the start of an impulsive wave three down, the decline could go well below 4,000, take out the recent lows around 3,900, and eventually take the S&P 500 to new lows. The chart of the cash market has a clear rhythm to it and, on top of that, has a bearish ascending broadening wedge pattern.

NASDAQ (QQQ)

The QQQ has the same patterns as the S&P 500, with the ascending broadening wedge and the ending diagonal triangle, all suggesting we see lower prices. Like the S&P 500, the QQQ has merely retraced 38.2% of the recent drop. But unlike the S&P 500, the QQQ has already broken the lower bound of its broadening wedge, which may tell us what will happen next for the S&P 500.

TIP

The TIP ETF also has that same broadening wedge pattern as the S&P 500 and QQQ. Like the QQQ, the TIP ETF has also broken below the lower bound of the broadening wedge, which is a sign that the bearish pattern has already taken hold. Since we know that the QQQ ETF and the TIP ETF follow each other over time, it is not surprising to see the same pattern in the three charts.

2-Yr

The 2-Yr rate pushed higher on Friday, closing at a new cycle high of 3.56%. The 2-yr appears to have broken through resistance, and as I have noted before, if the Fed is serious about getting rates up to 4%, then the 2-yr rate should have a four-handle in the not too distant future.

Biotech (XBI)

Biotech did not participate in the rally on Friday, sure it was up, but fractionally compared to the outsized gains of the broader indexes. It also appears to have put in a potential reversal candle, while failing at its long-term downtrend.

Anyway, that is all I have for today.

-Mike

Charts used with the permission of Bloomberg Finance LP. This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.